JEJaime-Jürgen Eulert-Grehn

Jaime-Jürgen Eulert-Grehn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaime-Jürgen Eulert-Grehn has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Defibrillator generator replacements in patients with left ventricular assist device support: The risks of hematoma and infection

    by Jj Eulert-Grehn, I Sterner, F Schoenrath, J Stein, J Mulzer, S Kurz, P Lanmüller, F Barthel, A Unbehaun, C Klein, et al.


  • Interventional Procedures for Left Ventricular Assist Device-Associated Complications

    by Pia Lanmueller, Jaime-Juergen Eulert-Grehn, Axel Unbehaun, Christoph Klein, Matthias Hommel, Markus Kofler, Joerg Kempfert, Christoph Hoermandinger, Friedrich Kaufmann, Philipp Stawowy, et al.

    As patients on long-term left ventricular assist device (LVAD) face a substantial risk for open cardiac reoperation, interventional treatment approaches are becoming increasingly important in this population. We evaluated data of 871 patients who were on LVAD support between January 1, 2016 and December 1, 2020. Interventional treatments for LVAD-associated complications were performed in 76 patients. Seventeen patients underwent transcatheter aortic valve replacements (TAVR) and 61 patients underwent outflow graft interventions (OGI). TAVR improved symptoms in patients with severe symptomatic aortic regurgitation. Postinterventional complications included aggravation of preexisting right heart failure (RHF), third-degree atrioventricular block, and intrapump thrombosis (in 3 [16.7%], 2 [11.1%], and 1 [5.6%] patients, respectively). In outflow graft obstructions, OGI led to recovery of LVAD flow (p < 0.001), unloading of the left ventricle (p = 0.004), decrease of aortic valve opening time (p = 0.010), and improvement of right heart function (p < 0.001). Complications included bleeding, RHF, and others (in 9 [10.8%], 5 [6.0%], and 5 [6.0%] patients, respectively). Eight (9.6%) patients died within the hospital stay after OGI, including mortality secondary to prolonged cardiogenic shock. In conclusion, interventional procedures are a feasible and safe treatment modality for LVAD-associated complications.


  • Transcatheter Aortic Valve Implantation for Severe Aortic Regurgitation in Patients with Left Ventricular Assist Device Support

    by P. Lanmueller, J. J. Eulert-Grehn, A. Unbehaun, C. Klein, M. Hommel, M. Kofler, J. Kempfert, C. Hörmadinger, F. Kaufmann, P. Stawowy, et al.

    Background: Approximately 15% of patients on left ventricular assist device (LVAD) support develop severe aortic regurgitation (AR). Since patients on LVAD support are considered at high risk for reoperation, the interventional approach is becoming increasingly important in this patient cohort. Method: We conducted a retrospective analysis to evaluate the outcomes of patients on LVAD support, who underwent transcatheter aortic valve implantation (TAVI) at our institution between January 1, 2016, and December 1, 2020. Results: During the investigational period, 18 TAVI were performed in LVAD patients at our institution. Mean age was 62.4 (±9.6) years and 72.2% were male. Before LVAD implantation, no or mild AR was pre-existing. The time from LVAD implantation to severe AR ranged from 0.5 to 9.5 years. Seventeen (94.4%) interventions were performed via femoral access. In total 18 (78.3%) balloon-expandable valves and 5 (21.7%) self-expandable valves were implanted. Six (35.3%) patients showed trans-stent leak after valve implantation and were treated with valve-in-valve implantation. In five patients the implantation was performed during the same procedure, in one patient 69 days after index procedure. Overall, technical success according to the Valve Academic Research Consortium 3 (VARC-3) was achieved in 72.2% cases. 33.3% of patients were directly transferred from the recovery room to the normal ward; 50.0% of patients spent 1 or 2 days in the intensive care unit. The median length of hospital stay was 7.5 (4.5–20.75) days. Pre intervention, all patients presented with symptoms of HF of functional New York Heart Association class 3 or 4. After TAVI 77.8% of patients had no or only mild symptoms. In two patients minor vascular and access-related complications (as determined by VARC-3) occurred: one patient required endovascular stenting of the common femoral artery and the other conservative treatment of an arteriovenous fistula. Two patients suffered from third-degree atrioventricular block. One patient developed LVAD intra-pump thrombosis. No patient suffered from VARC type ≥ 2 bleeding. Post-TAVI right heart failure with need for inotropic support was seen in three patients, of which one died within the hospital stay. Another patient died due to sepsis of unknown origin in an external hospital. This resulted in an all-cause mortality of 10.2% at 30 days. Conclusion: TAVI is a safe and feasible way to treat severe aortic regurgitation in patients on LVAD support. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Continuous-flow biventricular mechanical support implantation strategies

    by Jaime-Jürgen Eulert-Grehn, Pia Lanmüller, Christoph Starck, Felix Hennig, Stephan Jacobs, Volkmar Falk, Evgenij Potapov

    Continuous-flow biventricular mechanical support implantation strategies


  • Hemoptysis due to a primary aortobronchial fistula of the ascending aorta

    by Jaime-Jürgen Eulert-Grehn, Jana Veit, Volkmar Falk, Volker Düsterhöft

    European Journal of Cardio-Thoracic Surgery thanks Luca Di Marco, Stoyan Kostadinov Kondov and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

  • ECMELLA 2.0: Single Arterial Access Technique for a Staged Approach in Cardiogenic Shock

    by Jaime-Jürgen Eulert-Grehn, Christoph Starck, Jörg Kempfert, Volkmar Falk, Evgenij Potapov


  • Safety of bioelectrical impedance analysis in advanced heart failure patients

    by Luise Roehrich, Simon Suendermann, Isabell Anna Just, Jan Knierim, Johanna Mulzer, Marcus Mueller, Jaime‐Juergen Eulert‐Grehn, Manfred Hummel, Christoph Starck, Evgenij Potapov, et al.

    Background: Cardiac cachexia and frailty are major complications of advanced heart failure (AHF). Bioelectrical impedance analysis (BIA) may provide valuable information regarding fluid balance, muscle mass and prognosis. The main concerns regarding the use of BIA in AHF patients remain arrhythmias and electromagnetic interferences with cardiac implantable electronic devices (CIEDs). Reliable data regarding patients on continuous‐flow ventricular assist device (cf‐VAD) remain scarce. The aim of this study is to evaluate the safety of BIA in AHF patients on pro‐arrhythmogenic therapy with an implanted CIED and/or with a cf‐VAD.Methods: We prospectively performed 217 BIA measurements in 143 AHF patients at risk of severe arrhythmias due to inotropic support/a history of ventricular arrhythmias and/or treated with CIED, including 104 patients with an ICD, CRT or pacemaker and 95 patients with a cf‐VAD. All patients were under continuous Electrocardiogram (ECG) monitoring and clinical surveillance for 24 hours.Results: No adverse events were observed during the 217 BIA measurements: No rhythm disturbances were documented in the telemetric monitoring during or within 30 minutes after the measurement. CIEDs showed no malfunction, regardless of the location measured or the device manufacturer. In particular, no inappropriate shocks were observed. No alarms, flow disturbances, or malfunctions of the cf‐VAD occurred during or after the measurements.Conclusion: We consider BIA a safe measurement with major clinical relevance in our cohort of AHF patients, despite an increased arrhythmic potential on inotropic support or the presence of implanted electronic devices (ICD, CRT, pacemaker and cf‐VAD).


  • Open Access

    Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction

    by Christoph T Starck, Raymond H M Schaerf, Alexander Breitenstein, Sasan Najibi, John Conrad, Joseph Berendt, Fardad Esmailian, Jürgen Eulert-Grehn, Thomas Dreizler, Volkmar Falk

    Aims: Treatment of patients with systemic cardiac implantable electronic device (CIED) infection with large lead vegetations is challenging and associated with relevant morbidity and mortality. To avoid complications from open surgical extraction, a novel approach with percutaneous aspiration of large vegetations prior to transvenous lead extraction was instituted. The results of this treatment concept were retrospectively analysed in this multicentre study. Methods and results: One hundred and one patients [mean age 68.2 ± 13.1 (30–92) years] were treated in four centres for endovascular CIED infection with large lead vegetations. Mean lead vegetation size was 30.7 ± 13.5 mm. Two hundred and forty-seven leads were targeted for extraction (170 pacemaker leads, 77 implantable cardioverter-defibrillator leads). Mean lead implant duration was 81.7 (1–254) months. The transcatheter aspiration system with a specialized long venous drainage cannula and a funnel-shaped tip was based on a veno-venous extracorporeal circuit with an in-line filter. The aspiration of vegetations showed complete procedural success in 94.0% (n = 95), partial success in 5.0% (n = 5). Three major complications (3.0%) were encountered. Complete procedural success (per lead) of the subsequently performed transvenous lead extraction procedure was 99.2% (n = 245). Thirty-day mortality was 3.0% (n = 3). Five patients (5.0%) died in the further course on Days 51, 54, 68, 134, and 182 post-procedure (septic complications: n = 4; heart failure: n = 1). Conclusion: The percutaneous aspiration procedure is highly effective and is associated with a low complication profile. The aspiration of vegetations immediately prior and during the lead extraction procedure may avoid septic embolization into the pulmonary circulation. This may potentially lead to a long-term survival benefit.


  • Externalized conductor of a Kentrox lead and an unexpected insulation failure

    by Jaime-Jürgen Eulert-Grehn, Volkmar Falk, Mir Timo Nazari-Shafti, Christoph Starck

    Cardiac resynchronization therapy-defibrillator device upgrades may represent a challenging scenario, especially because unexpected findings can increase procedure difficulty. One such unexpected finding represents insulation failure with unremarkable device interrogation. Insulation failure due to an externalized conductor of an implantable cardiac defibrillator-lead has been recently described for the Kentrox lead (Biotronik). Another challenging aspect of device upgrades is the presence of venous thrombosis as in this case. Here, we report an inside-out abrasion of a Kentrox lead, an unexpected second insulation failure found during pocket revision and the successful recanalization in a patient with known left subclavian vein thrombosis.


  • Inadvertent pacemaker lead dislodgement

    by Jaime‐Jürgen Eulert‐Grehn, Gerard Schmidt, Jörg Kempfert, Christoph Starck

    Transcatheter aortic valve implantation (TAVI) has become an established treatment option for aortic valve stenosis in patients with a high risk for conventional surgical valve replacement. A well‐known complication is the development of conduction abnormalities. In the case of a new third‐degree atrioventricular block, the complication can be life‐threatening and permanent pacing is needed. Often these patients have a venous sheath placed in the jugular vein for the perioperative period. We report a case of inadvertent dislodgement of a permanent pacemaker lead after removal of a preoperatively placed venous sheath in a TAVI patient.